Immunomic Therapeutics negotiated an exclusive license to Annias Immunotherapeutics’ platform covering technology for targeting cytomegalovirus (CMV) antigens in cancer. The CMV immunotherapy platform was developed by John H. Sampson, M.D., Ph.D., and Duane A. Mitchell, M.D., Ph.D., at Duke University and licensed to Annias. Immunomic will combine the CMV platform with its own nucleic acid-based immunotherapy LAMP-Vax™ technology as a potential treatment for cancers that express CMV, including glioblastoma multiforme (GBM). Financial details of the licensing agreement were not disclosed